The results of CD44/CD24 staining in two of the triple-negative breast cancer cell lines tested (MCF10AT and MCF10CA1α) indicated an overall increase in mesenchymal-like CSC population after treatment with Efavirenz (Figure 4A,B), opposite to the results obtained for epithelial-like CSCs. The gene discussed is CD24; the disease is triple-negative breast carcinoma.